{"id":"sar231893","safety":{"commonSideEffects":[{"rate":null,"effect":"Testosterone suppression"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SAR231893 binds to and activates the androgen receptor with preferential activity in muscle and bone tissues while minimizing activity in prostate and other androgen-sensitive tissues. This selective tissue activation aims to provide anabolic benefits (muscle and bone strengthening) while reducing unwanted androgenic side effects associated with traditional androgens.","oneSentence":"SAR231893 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:32.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting and weakness in aging males"},{"name":"Osteoporosis and bone loss"}]},"trialDetails":[{"nctId":"NCT07053423","phase":"PHASE4","title":"A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":218},{"nctId":"NCT06693531","phase":"","title":"A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-22","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":350},{"nctId":"NCT06191315","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-01-03","conditions":"Wheezing, Asthma","enrollment":90},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07112378","phase":"PHASE3","title":"A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-10","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":20},{"nctId":"NCT04287621","phase":"","title":"Registry of Asthma Patients Initiating DUPIXENT®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-03-02","conditions":"Asthma","enrollment":718},{"nctId":"NCT04550962","phase":"","title":"Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-11-02","conditions":"Asthma","enrollment":376},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT06687967","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-28","conditions":"Lichen Simplex Chronicus","enrollment":142},{"nctId":"NCT06687980","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-25","conditions":"Lichen Simplex Chronicus","enrollment":138},{"nctId":"NCT06293053","phase":"PHASE3","title":"A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-05-15","conditions":"Prurigo Nodularis","enrollment":18},{"nctId":"NCT05590585","phase":"PHASE4","title":"Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-11","conditions":"Moderate-to-Severe Atopic Dermatitis, Atopic Eczema","enrollment":124},{"nctId":"NCT04684524","phase":"PHASE3","title":"Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-01","conditions":"Allergic Fungal Rhinosinusitis","enrollment":62},{"nctId":"NCT07187089","phase":"PHASE4","title":"Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-11","conditions":"Severe Atopic Dermatitis (AD)","enrollment":""},{"nctId":"NCT03560466","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-21","conditions":"Asthma","enrollment":378},{"nctId":"NCT04394351","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-01","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":102},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT05831176","phase":"PHASE2","title":"A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-03","conditions":"Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID)","enrollment":22},{"nctId":"NCT04776694","phase":"","title":"Compassionate Use of Dupilumab","status":"APPROVED_FOR_MARKETING","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Type 2 Inflammatory Disorders","enrollment":""},{"nctId":"NCT05976386","phase":"PHASE1","title":"Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-08","conditions":"Healthy Volunteers","enrollment":182},{"nctId":"NCT04447417","phase":"PHASE4","title":"Dupilumab Skin Barrier Function Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-16","conditions":"Atopic Dermatitis","enrollment":52},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT04033367","phase":"PHASE4","title":"SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-22","conditions":"Atopic Dermatitis","enrollment":188},{"nctId":"NCT04823130","phase":"PHASE4","title":"Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-04-22","conditions":"Dermatitis Atopic","enrollment":54},{"nctId":"NCT05991323","phase":"","title":"Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-12-12","conditions":"Prurigo Nodularis","enrollment":100},{"nctId":"NCT04718870","phase":"PHASE4","title":"Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-02-19","conditions":"Dermatitis Atopic","enrollment":41},{"nctId":"NCT04678882","phase":"PHASE3","title":"Dupilumab in Japanese Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-01-15","conditions":"Atopic Dermatitis","enrollment":62},{"nctId":"NCT05049122","phase":"PHASE4","title":"Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-10-22","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":25},{"nctId":"NCT04681729","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-10","conditions":"Cold Urticaria","enrollment":82},{"nctId":"NCT04400318","phase":"PHASE4","title":"The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-20","conditions":"Asthma","enrollment":109},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT06087627","phase":"","title":"A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-27","conditions":"Prurigo Nodularis","enrollment":150},{"nctId":"NCT04959448","phase":"","title":"Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-08-12","conditions":"Chronic Rhinosinusitis With Nasal Polyposis","enrollment":717},{"nctId":"NCT06169527","phase":"","title":"A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-11-28","conditions":"Atopic Dermatitis","enrollment":303},{"nctId":"NCT03992417","phase":"","title":"Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2019-06-11","conditions":"Dermatitis Atopic","enrollment":955},{"nctId":"NCT05906706","phase":"","title":"Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid","status":"APPROVED_FOR_MARKETING","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Bullous Pemphigoid","enrollment":""},{"nctId":"NCT02612454","phase":"PHASE3","title":"Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-10-15","conditions":"Atopic Dermatitis","enrollment":880},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT04442269","phase":"PHASE2","title":"Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":62},{"nctId":"NCT04678856","phase":"PHASE3","title":"Dupilumab in CRSsNP","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-02","conditions":"Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis","enrollment":71},{"nctId":"NCT06631677","phase":"","title":"Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)","status":"NO_LONGER_AVAILABLE","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Food Allergy","enrollment":""},{"nctId":"NCT04502862","phase":"PHASE4","title":"A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-08-10","conditions":"Asthma","enrollment":202},{"nctId":"NCT04203797","phase":"PHASE4","title":"A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-16","conditions":"Asthma","enrollment":40},{"nctId":"NCT06192563","phase":"","title":"A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-11-30","conditions":"Dermatitis Atopic","enrollment":150},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT04417894","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-14","conditions":"Moderate to Severe Atopic Hand and Foot Dermatitis","enrollment":133},{"nctId":"NCT03912259","phase":"PHASE3","title":"Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-12-19","conditions":"Atopic Dermatitis","enrollment":165},{"nctId":"NCT01949311","phase":"PHASE3","title":"Open-label Study of Dupilumab in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-10-10","conditions":"Atopic Dermatitis","enrollment":2733},{"nctId":"NCT05976360","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-11-02","conditions":"Healthy Volunteer","enrollment":38},{"nctId":"NCT05976373","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-05","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT03633617","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-09-24","conditions":"Eosinophilic Esophagitis","enrollment":321},{"nctId":"NCT04287608","phase":"","title":"Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-03-10","conditions":"Conjunctivitis, Atopic Dermatitis","enrollment":50},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT03782532","phase":"PHASE3","title":"Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-01-25","conditions":"Asthma","enrollment":486},{"nctId":"NCT03346434","phase":"PHASE2, PHASE3","title":"Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-30","conditions":"Dermatitis, Atopic","enrollment":202},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT03793608","phase":"PHASE2","title":"Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-03-12","conditions":"Peanut Allergy","enrollment":25},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT02134028","phase":"PHASE3","title":"Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08-05","conditions":"Asthma","enrollment":2282},{"nctId":"NCT02407756","phase":"PHASE2","title":"A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-31","conditions":"Atopic Dermatitis","enrollment":78},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT02277769","phase":"PHASE3","title":"Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-11-30","conditions":"Dermatitis, Atopic","enrollment":708},{"nctId":"NCT03558997","phase":"PHASE2","title":"Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-06-07","conditions":"Allergic Rhinitis","enrollment":103},{"nctId":"NCT02210780","phase":"PHASE2","title":"Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-08-05","conditions":"Atopic Dermatitis","enrollment":194},{"nctId":"NCT01979016","phase":"PHASE2","title":"Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-12-31","conditions":"Atopic Dermatitis (AD)","enrollment":54},{"nctId":"NCT02395133","phase":"PHASE3","title":"A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-25","conditions":"Atopic Dermatitis","enrollment":422},{"nctId":"NCT02379052","phase":"PHASE2","title":"Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-05-12","conditions":"Eosinophilic Esophagitis","enrollment":47},{"nctId":"NCT01385657","phase":"PHASE1","title":"Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-07-31","conditions":"Atopic Dermatitis","enrollment":37},{"nctId":"NCT02898454","phase":"PHASE3","title":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-28","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":448},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT02912468","phase":"PHASE3","title":"A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-05","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":276},{"nctId":"NCT02414854","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04-27","conditions":"Asthma","enrollment":1902},{"nctId":"NCT01548404","phase":"PHASE2","title":"Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-04","conditions":"Atopic Dermatitis","enrollment":109},{"nctId":"NCT02277743","phase":"PHASE3","title":"Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-10","conditions":"Dermatitis, Atopic","enrollment":671},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01639040","phase":"PHASE2","title":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":31},{"nctId":"NCT01859988","phase":"PHASE2","title":"Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-05","conditions":"Atopic Dermatitis","enrollment":380},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01920893","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-08","conditions":"Nasal Polyps","enrollment":60},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT02647086","phase":"PHASE1","title":"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-12","conditions":"Atopic Dermatitis","enrollment":14},{"nctId":"NCT01537653","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT01537640","phase":"PHASE1","title":"Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT01015027","phase":"PHASE1","title":"Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT01259323","phase":"PHASE1","title":"Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2010-12","conditions":"Dermatitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"EOSINOPHILIA"},{"count":2,"reaction":"ANAPHYLACTIC REACTION"},{"count":2,"reaction":"ECZEMA"},{"count":2,"reaction":"ERYTHEMA NODOSUM"},{"count":2,"reaction":"PNEUMONIA"},{"count":2,"reaction":"PRURITUS"},{"count":1,"reaction":"ABORTION SPONTANEOUS"},{"count":1,"reaction":"ADENOCARCINOMA GASTRIC"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"ANGINA PECTORIS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dupixent"],"phase":"marketed","status":"active","brandName":"SAR231893","genericName":"SAR231893","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAR231893 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner. Used for Muscle wasting and weakness in aging males, Osteoporosis and bone loss.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}